-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, with the continuous implementation of a series of medical reform policies, such as mass procurement, consistency evaluation, etc.
, the domestic pharmaceutical market has begun to see more and more changes
.
In this context, many multinational pharmaceutical companies have begun to adapt and transform themselves to respond to changing policies
.
Among them, it is worth noting that more and more "China Innovation Centers" are constantly emerging
.
On October 11, AstraZeneca, a multinational pharmaceutical company, officially opened its Global R&D China Center in Shanghai
.
It is reported that the R&D center was officially announced by AstraZeneca during the 2019 China International Import Expo
.
As an important member of AstraZeneca’s global R&D network, this global R&D China center will deeply participate in AstraZeneca’s global new drug R&D, from R&D pipeline layout, R&D strategy formulation, to full life cycle product development and launch; covering tumor, respiratory, A wide range of diseases such as immunity, cardiovascular, kidney, metabolism, and rare diseases
.
After the establishment of the center, it is expected that while realizing the simultaneous research and development of new drugs worldwide and further addressing China's unmet medical needs, it will also participate in and strive to guide the further development of global early research and development
.
In fact, as far as the author understands, since entering China in 1993, AstraZeneca has continued to develop and expand its deployment and investment in China's biomedicine field, and has continuously promoted local innovation practices in various fields such as drug research and development
.
For example, in 2007, AstraZeneca invested in the establishment of the China Innovation Center in China; in 2013, it established the China New Drug R&D Department to support the clinical development and marketing of AstraZeneca's innovative drugs in China
.
In 2021, AstraZeneca's innovative version will accelerate its expansion
.
In May, the Life and Health Industry Chain Summit and the sailing ceremony of AstraZeneca North China Headquarters were successfully held in Beijing Economic and Technological Development Zone
.
In July, AstraZeneca also announced the official opening of its Eastern China headquarters in Hangzhou, Zhejiang Province
.
At present, under AstraZeneca's continuous deployment, its R&D pipeline in China has more than 120 projects under development, and more than 85% of the projects developed simultaneously with the global pipeline
.
The focus of the Global R&D China Center has also been expanded from conducting confirmatory research in China and supporting the launch of new drugs to earlier R&D
.
In fact, more and more multinational companies are cooperating with China's local innovation with a more open and cooperative attitude
.
It is reported that, in addition to AstraZeneca, Novo Nordisk, Johnson & Johnson, Boehringer Ingelheim, Roche and other companies are actually deploying global new drug research and development through the strong domestic support for innovative drug research and development
.
For example, on July 2, 2020, Boehringer Ingelheim has also announced the official launch of the China External Innovation Cooperation Center
.
The center adopts the first "three-in-one" business model among multinational pharmaceutical companies, integrating academic cooperation (cross-border research), business development and licensing, and venture capital, and is committed to bringing Chinese innovation into Boehringer Ingelheim drug discovery Value chain
.
On the whole, more and more multinational pharmaceutical companies are actively exploring cooperation with Chinese local innovative companies or projects in the form of "China Innovation Center" or "Innovation Open Platform"
.
According to this trend, the industry predicts that in the future, accelerating the listing of new drugs in China, placing global new drugs in China for the first time, and cooperating with domestic institutions and companies to develop new drugs will become common models for multinational pharmaceutical companies to deploy the domestic pharmaceutical industry
.
, the domestic pharmaceutical market has begun to see more and more changes
.
In this context, many multinational pharmaceutical companies have begun to adapt and transform themselves to respond to changing policies
.
Among them, it is worth noting that more and more "China Innovation Centers" are constantly emerging
.
On October 11, AstraZeneca, a multinational pharmaceutical company, officially opened its Global R&D China Center in Shanghai
.
It is reported that the R&D center was officially announced by AstraZeneca during the 2019 China International Import Expo
.
As an important member of AstraZeneca’s global R&D network, this global R&D China center will deeply participate in AstraZeneca’s global new drug R&D, from R&D pipeline layout, R&D strategy formulation, to full life cycle product development and launch; covering tumor, respiratory, A wide range of diseases such as immunity, cardiovascular, kidney, metabolism, and rare diseases
.
After the establishment of the center, it is expected that while realizing the simultaneous research and development of new drugs worldwide and further addressing China's unmet medical needs, it will also participate in and strive to guide the further development of global early research and development
.
In fact, as far as the author understands, since entering China in 1993, AstraZeneca has continued to develop and expand its deployment and investment in China's biomedicine field, and has continuously promoted local innovation practices in various fields such as drug research and development
.
For example, in 2007, AstraZeneca invested in the establishment of the China Innovation Center in China; in 2013, it established the China New Drug R&D Department to support the clinical development and marketing of AstraZeneca's innovative drugs in China
.
In 2021, AstraZeneca's innovative version will accelerate its expansion
.
In May, the Life and Health Industry Chain Summit and the sailing ceremony of AstraZeneca North China Headquarters were successfully held in Beijing Economic and Technological Development Zone
.
In July, AstraZeneca also announced the official opening of its Eastern China headquarters in Hangzhou, Zhejiang Province
.
At present, under AstraZeneca's continuous deployment, its R&D pipeline in China has more than 120 projects under development, and more than 85% of the projects developed simultaneously with the global pipeline
.
The focus of the Global R&D China Center has also been expanded from conducting confirmatory research in China and supporting the launch of new drugs to earlier R&D
.
In fact, more and more multinational companies are cooperating with China's local innovation with a more open and cooperative attitude
.
It is reported that, in addition to AstraZeneca, Novo Nordisk, Johnson & Johnson, Boehringer Ingelheim, Roche and other companies are actually deploying global new drug research and development through the strong domestic support for innovative drug research and development
.
For example, on July 2, 2020, Boehringer Ingelheim has also announced the official launch of the China External Innovation Cooperation Center
.
The center adopts the first "three-in-one" business model among multinational pharmaceutical companies, integrating academic cooperation (cross-border research), business development and licensing, and venture capital, and is committed to bringing Chinese innovation into Boehringer Ingelheim drug discovery Value chain
.
On the whole, more and more multinational pharmaceutical companies are actively exploring cooperation with Chinese local innovative companies or projects in the form of "China Innovation Center" or "Innovation Open Platform"
.
According to this trend, the industry predicts that in the future, accelerating the listing of new drugs in China, placing global new drugs in China for the first time, and cooperating with domestic institutions and companies to develop new drugs will become common models for multinational pharmaceutical companies to deploy the domestic pharmaceutical industry
.
